Holen Sie sich die Stockscreener-App
20.01
0.25%
-0.05
Handel nachbörslich:
20.20
0.19
+0.95%
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Automated trading signals detected on Tonix Pharmaceuticals Holding Corp.Trade Risk Summary & Daily Technical Forecast Reports - newser.com
Tonix CEO presents anti-CD154 antibody research at Japan transplant congress - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Highlights Advancements in Transpla - GuruFocus
How Tonix Pharmaceuticals Holding Corp. stock performs after earningsJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Tonix Pharmaceuticals Presented an Update on Fc-modified - GlobeNewswire
Phase 1 safety & biomarker data lead Tonix's TNX-1500 toward Phase 2 for kidney transplant prevention - Stock Titan
Using portfolio simulators with Tonix Pharmaceuticals Holding Corp. included2025 Bull vs Bear & Growth Focused Entry Point Reports - newser.com
How to recover losses in Tonix Pharmaceuticals Holding Corp. stock2025 Support & Resistance & Low Risk High Reward Trade Ideas - newser.com
Can Tonix Pharmaceuticals Holding Corp. recover in the next quarterJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
Tonix Pharmaceuticals Holding Corp. stock retracement – recovery analysisWeekly Trade Review & AI Forecast Swing Trade Picks - newser.com
Backtesting results for Tonix Pharmaceuticals Holding Corp. trading strategiesWeekly Market Outlook & Daily Profit Focused Screening - newser.com
Analyzing Tonix Pharmaceuticals Holding Corp. with risk reward ratio chartsJuly 2025 Breakouts & Smart Money Movement Tracker - newser.com
Tonix Pharmaceuticals Holding Corp. stock daily chart insightsJuly 2025 PostEarnings & High Return Trade Opportunity Guides - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Tonix Pharmaceuticals (NASDAQ:TNXP) - MarketBeat
Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK - Barchart.com
Fibromyalgia Market Expected to Gain Momentum Through 2034, - openPR.com
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 - The Manila Times
Single‑Dose TNX-801 Mpox Vaccine: Tonix to Present Safety & Durability Data at World Vaccine Congress Europe - Stock Titan
Detecting price anomalies in Tonix Pharmaceuticals Holding Corp. with AI2025 Sector Review & Real-Time Buy Signal Notifications - newser.com
What analysts say about Tonix Pharmaceuticals Holding Corp stockResistance Breakout Alerts & Affordable Growth Strategies - earlytimes.in
Tonix Pharmaceuticals (TNXP) Plans New Phase 2 Trials for Key Tr - GuruFocus
Tonix Pharma Plans Phase 2 Trial for 2026 - TipRanks
Tonix to advance cyclobenzaprine into phase 2 for depression - Seeking Alpha
Is Tonix Pharmaceuticals Holding Corp. trending in predictive chart models2025 Investor Takeaways & Daily Price Action Insights - newser.com
Custom watchlist performance reports with Tonix Pharmaceuticals Holding Corp.2025 Valuation Update & Safe Capital Growth Tips - newser.com
What data driven models say about Tonix Pharmaceuticals Holding Corp.’s futureWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Tonix Pharmaceuticals advances TNX-2900 into Phase 2 trial for Prader-Willi Syndrome - Proactive financial news
Tonix Pharma Appoints New Head of Market Access - MSN
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access - Sahm
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access By Investing.com - Investing.com Nigeria
Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury
Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome to Phase 2 Clinical Trial - citybuzz
Tonix Pharmaceuticals Further Strengthens Commercial - GlobeNewswire
Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access - citybiz
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain? - PharmaVoice
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access - Investing.com
Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access Ahead of Tonmya™ Launch for Fibromyalgia Treatment - Quiver Quantitative
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):